CoChat

Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis

Open access
Shepherd, Emma L., Saborano, Raquel, Northall, Ellie, Matsuda, Kae, Ogino, Hitomi, Yashiro, Hiroaki, Pickens, Jason, Feaver, Ryan E., Cole, Banumathi K., Hoang, Stephen A., Lawson, Mark J., Olson, Matthew, Figler, Robert A., Reardon, John E., Nishigaki, Nobuhiro, Wamhoff, Brian R., Günther, Ulrich L., Hirschfield, Gideon, Erion, Derek M., Lalor, Patricia F. · 2021 · JHEP Reports
Cited by 70

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background & Aims Increasing evidence highlights dietary fructose as a major driver of non-alcoholic fatty liver disease (NAFLD) pathogenesis, the majority of which is cleared on first pass through the hepatic circulation by enzymatic phosphorylation to fructose-1-phosphate via the ketohexokinase (KHK) enzyme. Without a current approved therapy, disease management emphasises lifestyle interventions, but few patients adhere to such strategies. New targeted therapies are urgently required. Methods We have used a unique combination of human liver specimens, a murine dietary model of NAFLD and human multicellular co-culture systems to understand the hepatocellular consequences of fructose administration. We have also performed a detailed nuclear magnetic resonance-based metabolic tracing of the fate of isotopically labelled fructose upon administration to the human liver. Results Expression of KHK isoforms is found in multiple human hepatic cell types, although hepatocyte expression predominates. KHK knockout mice show a reduction in serum transaminase, reduced steatosis and altered fibrogenic response on an Amylin diet. Human co-cultures exposed to fructose exhibit steatosis and activation of lipogenic and fibrogenic gene expression, which were reduced by pharmacological inhibition of KHK activity. Analysis of human livers exposed to 13 C-labelled fructose confirmed that steatosis, and associated effects, resulted from the accumulation of lipogenic precursors (such as glycerol) and enhanced glycolytic activity. All of these were dose-dependently reduced by administration of a KHK inhibitor. Conclusions We have provided preclinical evidence using human livers to support the use of KHK inhibition to improve steatosis, fibrosis, and inflammation in the context of NAFLD. Lay summary We have used a mouse model, human cells, and liver tissue to test how exposure to fructose can cause the liver to store excess fat and become damaged and scarred. We have then inhibited a key enzyme within the liver that is responsible for fructose metabolism. Our findings show that inhibition of fructose metabolism reduces liver injury and fibrosis in mouse and human livers and thus this may represent a potential route for treating patients with fatty liver disease in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhepr.2020.100217

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 70

Metadata

Authors
Shepherd, E. L., Saborano, R., Northall, E., Matsuda, K., Ogino, H., Yashiro, H., Pickens, J., Feaver, R. E., Cole, B. K., Hoang, S. A., Lawson, M. J., Olson, M., Figler, R. A., Reardon, J. E., Nishigaki, N., Wamhoff, B. R., Günther, U. L., Hirschfield, G., Erion, D. M., & Lalor, P. F.
Venue
JHEP Reports
Publisher
Elsevier BV
Published
2021-04
Volume
3
Issue
2
Pages
100217
ISSN
2589-5559 (ISSN-L)
OpenAlex
W3110042762
Cited by
70
References
9
FWCI
5.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. https://app.cochat.ai/papers/10.1016/j.jhepr.2020.100217
The paper
Shepherd, E. L., Saborano, R., Northall, E., Matsuda, K., Ogino, H., Yashiro, H., Pickens, J., Feaver, R. E., Cole, B. K., Hoang, S. A., Lawson, M. J., Olson, M., Figler, R. A., Reardon, J. E., Nishigaki, N., Wamhoff, B. R., Günther, U. L., Hirschfield, G., Erion, D. M., & Lalor, P. F. (2021). Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. JHEP Reports. https://doi.org/10.1016/j.jhepr.2020.100217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.